Sino Biopharmaceutical Limited has announced that its self-developed Class 1 innovative drug, TDI01 suspension, a "ROCK2 inhibitor," has been included in the Breakthrough Therapy Designation process by the Center for Drug Evaluation $(CDE)$ of the National Medical Products Administration of China. This designation is for the treatment of moderate to severe chronic graft-versus-host disease (cGVHD) in patients who have undergone at least one but no more than five prior lines of systemic therapy. TDI01 is an innovative, oral, and highly selective ROCK2 inhibitor, marking it as the first of its kind domestically developed in China. The company aims to provide more innovative and effective treatment options for patients through this development. The announcement highlights Sino Biopharmaceutical Limited's commitment to advancing healthcare solutions.